# EDGAR Filing Document

**Accession Number:** 0001703057
**File Stem:** 0001703057-26-000031
**Filing Date:** 2026-6
**Character Count:** 9114
**Document Hash:** 8f9c1956ca464247111a3c18ddb086cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001703057-26-000031.hdr.sgml**: 20260605

**ACCESSION NUMBER**: 0001703057-26-000031

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260601

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260605

**DATE AS OF CHANGE**: 20260605

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AbCellera Biologics Inc.
- **CENTRAL INDEX KEY:** 0001703057
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39781
- **FILM NUMBER:** 261067701

**BUSINESS ADDRESS:**
- **STREET 1:** 150 W 4TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V5Y 1G6
- **BUSINESS PHONE:** (604) 559-9005

**MAIL ADDRESS:**
- **STREET 1:** 150 W 4TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V5Y 1G6

?xml version='1.0' encoding='ASCII'? abcl-20260601

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**__________________________________________**

**FORM 8-K**

**__________________________________________**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): June 1, 2026**

**__________________________________________**

**AbCellera Biologics Inc.**

**(Exact name of registrant as specified in its charter)**

**__________________________________________**

---

| | | |
|:---|:---|:---|
| **British Columbia** | **001-39781** | **Not Applicable** |
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification Number)** |

---

---

| | |
|:---|:---|
| **150 W 4th Avenue** <br>**Vancouver, BC** | **V5Y 1G6** |
| **(Address of registrant's principal executive office)** | **(Zip code)** |

---

**(604) 559-9005**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

**__________________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common shares | ABCL | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

**Appointment of Director**

On June 1, 2026, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Victor Sandor as a new director. Dr. Sandor will serve until the Company's next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier resignation or removal.

The Board has affirmatively determined that Dr. Sandor is independent under the rules of The NASDAQ Stock Market LLC and the Company's Corporate Governance Guidelines. Dr. Sandor has not been appointed to serve on committees of the Board.

In connection with Dr. Sandor's service as a director, he will participate in the Company's Non-Employee Director Compensation Policy on the same terms as the Company's other non-employee directors, as previously disclosed in the Company's Definitive Proxy on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2026.

Dr. Sandor has no direct or indirect material interest in any transaction pursuant to Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Sandor and any other person pursuant to which Dr. Sandor was appointed as a member of the Board.

A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Press Release issued by AbCellera Biologics Inc. on](abcellera-appointsxdrxxv.htm)[Ju](abcellera-appointsxdrxxv.htm)[n](abcellera-appointsxdrxxv.htm)[e](abcellera-appointsxdrxxv.htm)[5](abcellera-appointsxdrxxv.htm)[, 2026](abcellera-appointsxdrxxv.htm)[.](abcellera-appointsxdrxxv.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 5, 2026 | **ABCELLERA BIOLOGICS INC.** | **ABCELLERA BIOLOGICS INC.** |
|  | By: | /s/ Carl L. G. Hansen |
|  |  | **Carl L. G. Hansen, Ph.D.** |
|  |  | **Chief Executive Officer and Director**<br>*(Principal Executive Officer)* |

---

## Exhibit 99.1

![](abcellera-appointsxdrxxv001.jpg)

150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Victor Sandor to its Board of Directors 2026-06-05 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. "Dr. Sandor is an experienced director and a distinguished medical oncologist with experience in building companies and bringing innovative medicines to patients in need," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "I am pleased to welcome Dr. Sandor to AbCellera's Board of Directors and look forward to working with him." Before its acquisition by P�zer Inc., Dr. Sandor served as Chief Medical O�cer at Array BioPharma Inc. where he successfully secured approval of Braftovi® (encorafenib) and Mektovi® (binimetinib). Prior to joining Array, Dr. Sandor served as Senior Vice President for Global Clinical Development at Incyte Corporation, where he played a critical role in the approval of Jaka�® (ruxolitinib). Dr. Sandor was also Vice President and Chief Medical O�cer for Oncology at Biogen Inc. and held positions of increasing responsibility in oncology product development at AstraZeneca Pharmaceuticals LP, contributing to the registration of Arimidex® (anastrozole) and the development of Faslodex® (fulvestrant). "I am excited to join the AbCellera board at this important moment in the company's evolution. AbCellera has established an exceptional capability in antibody discovery, and I look forward to working with Carl and the team as the company advances its pipeline and translates that capability into meaningful clinical outcomes for patients," 1

------

![](abcellera-appointsxdrxxv002.jpg)

said Dr. Sandor. Dr. Sandor currently serves on the board of directors at ADC Therapeutics SA, Kymera Therapeutics Inc., and Prelude Therapeutics Incorporated. He also served on the board of Merus N.V. prior to its acquisition by Genmab A/S in 2025. Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed a Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing �rst- in-class antibody-based medicines in the areas of endocrinology, women's health, immunology, oncology, and more. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116 Source: AbCellera Biologics Inc. 2

------